Veru (VERU) Non Operating Income (2012 - 2024)
Veru (VERU) posted quarterly Non Operating Income of $127783.0 for Q3 2024, down 78.76% year-over-year from $601511.0 in Q4 2023, and down 3.32% quarter-over-quarter from $132166.0 in Q2 2024.
Veru (VERU) Non Operating Income (2012 - 2024) Analysis & Trends
Veru (VERU) has reported Non Operating Income for 13 consecutive years, with $127783.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Non Operating Income fell 78.76% year-over-year to $127783.0; the TTM figure through Sep 2024 stood at -$160928.0 (down 114.5% YoY), while the FY2024 annual figure was -$160928.0, down 114.5% from the prior year.
- Non Operating Income eased to $127783.0 in Q3 2024 per VERU's latest filing, from $132166.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $3.7 million in Q3 2022 and bottomed at -$2.8 million in Q3 2021.
- Historically, Non Operating Income has averaged -$620132.3 across 5 years, with a median of -$643971.0 in 2020.
- Annual changes were most pronounced in 2021 — Non Operating Income slumped 110.08% — and 2023, when it soared 642.8%.
- Veru's Non Operating Income stood at -$1.9 million in 2020, then jumped by 30.73% to -$1.3 million in 2021, then dropped by 1.48% to -$1.3 million in 2022, then surged by 64.78% to -$465763.0 in 2023, then soared by 127.44% to $127783.0 in 2024.
- Business Quant data shows VERU's Non Operating Income at $127783.0 in Q3 2024, $132166.0 in Q2 2024, and $44886.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 127,783.00 |
| Jun 30, 2024 | 132,166.00 |
| Mar 31, 2024 | 44,886.00 |
| Dec 31, 2023 | -465,763.00 |
| Sep 30, 2023 | 601,511.00 |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 559,301.00 |
| Dec 31, 2022 | -1.32 Mn |
| Sep 30, 2022 | 3.66 Mn |
| Jun 30, 2022 | -234,198.00 |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -1.30 Mn |
| Sep 30, 2021 | -2.78 Mn |
| Jun 30, 2021 | -2.69 Mn |
| Mar 31, 2021 | -1.35 Mn |
| Dec 31, 2020 | -1.88 Mn |
| Sep 30, 2020 | -1.67 Mn |
| Jun 30, 2020 | -1.39 Mn |
| Mar 31, 2020 | -643,971.00 |
| Dec 31, 2019 | -1.60 Mn |